UNSPSC 51422334: Dexamethasone acetate anhydrous

This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7V8P532WP, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone acetate anhydrous, which bears US NIH Compound Identifier 14442.

UNSPSC 51422334 Dexamethasone acetate anhydrous is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The single recent opportunity associated with this code — Seminole County, Florida's IFB 60459723LAS — solicits Naloxone and Safe Drug Deactivation Systems, which fall outside the scope of dexamethasone acetate anhydrous pharmaceutical procurement. This mismatch suggests either a coding error in the opportunity record or a misclassification at the source. The code shows little relevant recent activity.

Seminole County posted the Naloxone and Drug Deactivation Systems IFB on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs in their bids, meet E-Verify and drug-free workplace certification requirements, carry workers' compensation and general liability insurance, and comply with federal environmental regulations. The contract carries an initial two-year term with a one-year renewal option and includes a three-month probationary termination clause.